An analysis from the PROSPECT study has identified two biomarkers that may help identify nonculprit lesions that will progress rapidly following percutaneous coronary intervention. The biomarkers sFLT-1 and GDF-15 were associated with risk of major adverse cardiovascular events, according to the analysis. The findings may help clinicians identify patients who will benefit from prophylactic stenting.